Pyc Therapeutics Share Price and Company Fundamentals



Price
$0.16
Change
0.005 (3.226%)
52 week
0.109257 - 0.203615

Last traded: Today at 6:10 AM

PYC Therapeutics Limited provides drug discovery services utilizing peptide libraries and proprietary screening capabilities in Australia. The company provides next generation delivery platform for cell-penetrating peptides (CPPs), a small biological molecule. The company's proprietary peptide libraries contain fragments from diverse and evolutionarily distinct microbial genomes - organisms which known as cell-penetrating properties. It develops CPP- Antisense Oligonucleotides (ASOs), a pipeline of drugs for the treatment of retinal disease. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.

Key Metrics

PE ratio

-

PB ratio

8.42

Dividend yield

Beta

0.63

Market cap

$508.95M

Enterprise value

$452.8M

Company profile

Primary activitiesBiotechnology research and development Peptide drug discovery
Industry / SectorBiotechnology / Healthcare
Websitehttp://pyctx.com
Mailing addressHarry Perkins Institute of Medical Resea 6 Verdun Street Nedlands WA 6009 Australia
Phone / Fax61 8 6151 0994 /
Share registryAUTOMIC REGISTRY SERVICES

Dividends

Pyc Therapeutics does not pay dividends.

Company Executives

As of Jul 2021, following are the company executives and directors listed on Pyc Therapeutics.

NameTitleAgeTotal Pay
Dr. Rohan Hockings MBBS, MBBS (Hons.), J.D., G.D.L.PCEO & Director37395k
Mr. Kevin Ronald Hart B.Com., F.C.A., B.Comm (Hons), FCACompany Sec. & CFO58
Prof. Sue FletcherChief Scientific Officer
Mr. Sahm Nasseri M.B.A., MBACEO of US operations & Director36
Mr. Kaggen Ausma L.L.B.Chief Bus. Officer
Dr. May OrfaliChief Medical Officer of US Operations
Dr. Glenn NoronhaChief Devel. Officer55

Profitability and management effectiveness

Profit margin

0.00%

Operating margin

-10,940.67%

Return on assets

-16.66%

Return on equity

-26.41%

Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of Pyc Therapeutics is 508.95M and its enterprise value is 452.8M. The enterprise value to revenue ratio of PYC is 3,746.81.

The PYC's stocks Beta value is 0.63 making it 37% less volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.

Companies similar to Pyc Therapeutics (PYC)

Pyc Therapeutics (ASX:PYC) Frequently Asked Questions

1. What is Pyc Therapeutics's Stock Symbol?

Pyc Therapeutics trades on ASX under the ticker symbol "PYC".

2. What is Pyc Therapeutics's stock price today?

One share of PYC stock can currently be purchased for approximately $0.16.

3. How can I contact Pyc Therapeutics?

Pyc Therapeutics's mailing address is Harry Perkins Institute of Medical Resea 6 Verdun Street Nedlands WA 6009 Australia. The company can be reached via phone at 61 8 6151 0994.

4. What is Pyc Therapeutics's official website?

The official website of Pyc Therapeutics is http://pyctx.com.

5. Which share registry manages Pyc Therapeutics's stock?

Pyc Therapeutics's stock is managed by AUTOMIC REGISTRY SERVICES.